Where mood shows up in the tablet’s documents
Mood is not a side-effect entry for Rybelsus® in any region. It appears in the patient information as part of the warning signs of hypoglycaemia [1][2][3].
| Document | Wording | Context |
|---|---|---|
| US Medication Guide [1] | Anxiety, irritability or mood changes; confusion or drowsiness | Signs of low blood sugar |
| Canadian Patient Medication Information [3] | Feeling nervous, anxious or confused; difficulty concentrating | Warning signs of low blood sugar |
| EU package leaflet, sections 2 and 4 [2] | Feeling nervous, anxious or confused; low blood sugar may reduce concentration | Warning signs of low blood sugar |
| US, EU and Canadian adverse-reaction sections [1][2][3] | No depression, anxiety or other psychiatric reaction listed | Trial and postmarketing data |
What regulators concluded
In January 2026 the FDA asked for a suicidal-thoughts warning to be removed from the labels of the three GLP-1 medicines approved for weight loss that carried it. It also pointed out that labels for GLP-1 medicines approved for type 2 diabetes, the group Rybelsus® belongs to, did not contain that information [4]. The decision rested on a meta-analysis of 91 placebo-controlled trials with 107,910 participants, which showed no increased risk of suicidal thoughts or behaviour, or of anxiety, depression, irritability or psychosis, and on a study of more than 2.2 million people with type 2 diabetes that found no higher risk of intentional self-harm with GLP-1 medicines than with SGLT2 inhibitors [4].
In Europe, the safety committee PRAC reviewed the same question from July 2023 and in April 2024 concluded that the evidence did not support a causal link. Novo Nordisk was among the companies asked for additional data, and Rybelsus® is named among the products reviewed; no change to the product information was considered necessary [5].
Trials of the tablet in people with depression
A randomised, double-blind trial at a Toronto mood-disorders unit gave oral semaglutide 14 mg or placebo, on top of usual treatment, to 72 adults with major depressive disorder and overweight or obesity for 16 weeks. The tablet did not change the severity of depressive symptoms or how often suicidal thoughts occurred; stomach side effects were common, and there were no serious adverse events [6]. A secondary analysis of the same trial reported that people on the tablet showed more willingness to make an effort for rewards, a measure of motivation [7]. These are small trials with short follow-up, but they are among the few that measured mood directly in people taking the tablet.
In US reports of suspected side effects with semaglutide tablets from 2019 to 2023, psychiatric events were reported less often than expected compared with other medicines (124 reports, reporting odds ratio 0.38) [8]. A US health-record study of people with type 2 diabetes prescribed semaglutide between late 2017 and mid-2021 found no higher 12-month risk of depression, anxiety, suicidality or other psychiatric outcomes than with sitagliptin, empagliflozin or glipizide; its abstract does not separate tablets from injections [9]. Observational data can reassure but cannot rule out an effect in an individual.
How the tablet could still change how you feel
- Low blood sugar: with insulin or a sulfonylurea, Rybelsus® raises the risk of hypoglycaemia, and the US label asks prescribers to teach you its signs. Irritability, anxiety and confusion before a meal can be part of that picture [1].
- Feeling unwell: nausea, diarrhoea and vomiting are most common early on, and Canada’s trial table lists fatigue in 3.7% on 7 mg and 2.8% on 14 mg against none on placebo [1][3]. Feeling sick and tired for weeks can weigh on mood.
- Changes in eating: decreased appetite is a common reaction [1]. MedlinePlus notes that overeating or not wanting to eat can itself be a symptom of depression, so a change in appetite is worth discussing rather than assuming it is only the medicine [10].
Other reasons mood can shift
MedlinePlus explains that depression can come from genetic, biological, environmental and psychological factors, that it is more common in women, partly because of hormonal changes around menstruation, pregnancy, after birth and at menopause, and that chronic conditions such as diabetes or heart disease often occur alongside it [10]. Some medicines and medical conditions, such as thyroid disorders, can cause symptoms that look like depression [10]. Stressful life events and a family history raise the risk further.
Symptoms do not always look like sadness: MedlinePlus lists losing interest in favourite activities, sleeping too much or too little, feeling hopeless, irritable or guilty, aches and digestive problems, more alcohol or drug use and pulling away from family and friends [10]. Men may appear angry or irritable rather than sad, and older adults may show fewer obvious signs.
What helps, according to official sources
The FDA advises people taking GLP-1 medicines to keep taking them as prescribed, to discuss concerns with their health care professional, and to report new or worsening depression, suicidal thoughts or unusual changes in mood or behaviour [4]. The Canadian leaflet adds that stopping Rybelsus® without your doctor may let blood sugar rise, so any change in treatment is best planned together [3].
For depression itself, MedlinePlus describes talking therapy with a mental health provider and, where needed, medicines such as antidepressants; it advises not stopping an antidepressant without first talking with your provider [10]. A diagnosis of depression requires symptoms most of the day, nearly every day, for at least two weeks, which is one reason a simple daily mood record can help an appointment.
If you are in crisis
Thoughts of death, suicide or self-harm are an emergency whatever their cause. In Türkiye, call 112. In the US, call or text 988 to reach the 988 Suicide & Crisis Lifeline, which is free, confidential and open 24 hours a day [4][11]. If you are worried about someone else, you can contact these services for them too, and stay with the person while help is on the way.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Thoughts of suicide, self-harm or death, in yourself or someone close to you | Türkiye: 112; US: call or text 988 | Emergency | FDA [4]; 988 Lifeline [11] |
| Confusion, fits or passing out on insulin or a sulfonylurea | Emergency services; this may be severe low blood sugar | Emergency | Canadian leaflet [3] |
| Irritability, anxiety, sweating or shakiness before meals on insulin or a sulfonylurea | Treat low blood sugar as you were taught, then tell your prescriber | Today | Rybelsus® Medication Guide [1] |
| New or worsening depression, or unusual changes in mood or behaviour | Your health care professional | Today | FDA [4] |
| Feeling down, or no interest in things you enjoy, nearly every day for at least two weeks | Your provider or a mental health provider | At your next appointment | MedlinePlus [10] |
